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ABSTRACT
The ability to engineer biological circuits that
process and respond to complex cellular signals
has the potential to impact many areas of biology
and medicine. Transcriptional activator-like ef-
fectors (TALEs) have emerged as an attractive
component for engineering these circuits, as TALEs
can be designed de novo to target a given DNA
sequence. Currently, however, the use of TALEs is
limited by degeneracy in the site-specific manner
by which they recognize DNA. Here, we propose an
algorithm to computationally address this problem.
We apply our algorithm to design 180 TALEs target-
ing 20bp cognate binding sites that are at least 3nt
mismatches away from all 20bp sequences in
putative2kbhumanpromoterregions.Wegenerated
eight of these synthetic TALE activators and showed
that each is able to activate transcription from a
targeted reporter. Importantly, we show that these
proteins do not activate synthetic reporters contain-
ing mismatches similar to those present in the
genome nor a set of endogenous genes predicted
to be the most likely targets in vivo. Finally, we
generated and characterized TALE repressors
comprised of our orthogonal DNA binding domains
and further combined them with shRNAs to accom-
plish near complete repression of target gene
expression.
INTRODUCTION
A central goal of synthetic biology is the creation of gene
regulatory circuits that speciﬁcally and robustly control
gene expression in response to cell state and environmen-
tal cues (1–4). While much progress has been made toward
developing genetic systems that detect biological signals,
the ability to integrate these signals has been limited by the
lack of modular and mutually orthogonal genetic elements
available for use. Additionally, the functionality of these
systems can be hampered by unwanted interference with
the host cell machinery. The generation of high-ﬁdelity
gene circuits would thus beneﬁt from a set of mutually
orthogonal synthetic regulatory components that have
minimal effects on endogenous cell machinery. In the
case of transcriptional systems, it would be ideal to have
a set of transcriptional regulators that would only target
DNA sequences that exist within the artiﬁcial circuit. Such
regulators would have minimal afﬁnity for DNA
sequences present in the endogenous promoter regions
of the host cell, thus minimizing unwanted effects on
host gene expression (Figure 1). Transcription factors
with programmable DNA binding domains offer one
potential approach toward this goal. Transcriptional
activator-like effectors (TALE) proteins have been
recently demonstrated to have modular and predictable
DNA binding domains, thereby allowing for the de novo
creation of synthetic transcription factors that bind any
DNA sequence of interest (5–10).
Originally discovered in phytopathogenic bacteria of
the genus Xanthomonas, TALE proteins are made up of
three distinct regions: (i) an N-terminal region housing the
protein secretion and translocation signals, (ii) a central
repeat domain composed of a series of tandem repeats
containing repeat variable di-residues (RVDs) that
speciﬁcally recognize and bind DNA and (iii) a
C-terminal domain containing two nuclear localization
signals (NLSs) and a transcriptional activation domain
(Figure 2A) (11–14). The central DNA-binding domain
is composed of a variable number of 33–35 amino acid
repeats such that each binding domain recognizes a differ-
ent DNA base pair (bp) and can be recombined to recog-
nize any given DNA sequence (12,15). Recent studies have
deciphered the code by which the repeat elements bind to
DNA, showing that the residues at amino acid positions
12 and 13 in each repeat determine which nucleotide is
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of these repeat elements has enabled TALEs to become a
powerful tool, allowing for the creation of synthetic
transcriptional activators that can target a speciﬁc DNA
sequence and activate a desired gene (6,7). Furthermore,
because of the proteins’ modular nature, TALEs are
amenable to hierarchical ligation-based construction
strategies, enabling the development of large libraries of
proteins (5,7,18–20).
At present, however, drawbacks to the use of TALEs as
targeted transcription factors exist. Most notably, each
TALE repeat does not bind to a given DNA base pair
with perfect complementarity (Figure 2B) (21,22). While
it has been shown that in some cases including a single
mismatch in the binding site of a given TALE can signiﬁ-
cantly inhibit its off-target activity, there are known
instances where designed TALEs have been demonstrated
to bind to unintended off-target DNA sequences that
differ from their cognate target sequence by up to 3 bp
(as deﬁned by the TALE binding code) (16,17). These
observations indicate that while a synthetic TALE can
be designed to efﬁciently target a given DNA sequence,
unintended off-target effects can frequently occur and may
limit the utility of TALEs for speciﬁcally controlling the
expression of a targeted gene (Supplementary Methods).
This limitation also restricts the application of TALEs
as components of synthetic circuits where orthogonality
to the host cell’s genome is an important constraint.
We have developed an algorithm that allows one to
computationally design TALEs with cognate binding
sites that are at least a given number of mismatches
away from a set of DNA sequences. We apply our algo-
rithm to design TALEs with 20bp cognate binding sites
that are at least 3nt mismatches away from all 2000bp
putative human promoter sequences and at least 4 nt
mismatches from 500bp putative human promoter
sequences. These TALEs represent a potentially
powerful set of insulated transcriptional regulators for
the construction of synthetic gene circuits. We generated
DNA constructs encoding eight of these TALEs as
transcriptional activators and assessed their function in
human cells. We demonstrate that each TALE effectively
activates transcription from its targeted binding site and
that the TALE activators are mutually orthogonal in their
activities. We also show that the TALEs do not activate
transcription from artiﬁcial promoters containing binding
sites comparable to potential off-target sites in human
Figure 1. Orthogonal TALEs as ideal regulatory components for insulated synthetic gene circuits. (A) Non-orthogonal TALEs designed to bind and
regulate gene expression of a synthetic gene circuit may also bind to cognate and off-target (containing mismatches) binding sequences in the
endogenous promoter regions in the genomic DNA. (B) Orthogonal TALEs bind and regulate gene expression of a synthetic gene circuit and have no
predicted binding sites in the endogenous promoter regions.
Figure 2. TALE protein architecture and DNA binding speciﬁcities.
(A) Schematic of a representative TALE protein with 18.5 repeat
variable di-residue (RVD) domains. Each RVD domain is composed
of 34 amino acids and differs only in the variable amino acids high-
lighted in red. The C-terminal RVD domain is a 15 amino acid half
repeat domain. The two endogenous NLS domains and the endogenous
activation domain (AD) present in naturally occurring TALEs were
replaced with SV40 NLSs and the VP64 activation domain, respect-
ively. (B) The amino acid sequences and the preferred target nucleotides
of RVD domains NI, HD, NG from AvrBs3 and RVD domain NK
from pthA2.
Nucleic Acids Research, 2012,Vol.40, No. 15 7585promoter regions and provide additional evidence that the
TALEs do not activate their closest off-target endogenous
genes. Finally, we use two of the TALE DNA binding
domains to generate TALE repressors and demonstrate
strong TALE-mediated repression of a reporter gene.
We further combine these TALE repressors with synthetic
shRNAs targeting the same reporter to obtain even
stronger, near complete gene repression. Our
methodologies and TALE transcription factors address a
major gap in synthetic biology and provide a new set of
tools toward the design of robust genetic circuits that
function orthogonally to the cells in which they are
utilized (23–26).
MATERIAL AND METHODS
Human genome DNA sequences
The sequences corresponding to the 2000bp regions
upstream of all annotated transcription start sites (TSSs)
in human RefSeq genes with annotated 50 untranslated
regions (UTRs) were downloaded from the UCSC
Genome browser website (http://genome.ucsc.edu/). If
multiple upstream regions per RefSeq gene were found
due to multiple annotates TSSs, then all upstream
regions were used for computing orthogonal 20-mers.
Downloaded sequence ﬁles correspond to the February
2009 assembly of the human genome (hg19, GRCh37
Genome Reference Consortium Human Reference 37).
Recombinant DNA constructs of TALEs and reporters
Amino acid sequences encoding all TALE constructs were
derived from the AvrBs3 amino acid sequence (GenBank
locus id. CAA34257.1), including sequences encoding the
sub-modules corresponding to the constant 50 region,
variable repeats regions (for di-residues HD, NI and NG)
and the constant 30 region. Within these sequences, the
naturally existing NLS regions and activation domains in
AvrBs3 were identiﬁed in the 30 constant region and
replaced with mammalian SV40 NLS and VP64 activation
domains. For TALE repressors, the VP64 activation
domain was replaced with the KRAB transcriptional
repressiondomain.DNAsequencesencodingthesecompo-
nents were codon-optimized for expression in human cells
and synthesized by Integrated DNA Technology
(Coralville, IA, USA). The exact positions and sequences
used are listed in Supplementary Methods. These compo-
nents were combined to generate TALE expression
constructs using a hierarchal cloning scheme outlined in
Supplementary Methods. t2A and mCherry were
combined to full length TALE activator coding regions
and t2A and DsRed-shRNA constructs were combined to
full-length TALE repressor coding regions using BioBrick
cloning. These complete coding regions were cloned into
the NheI and NotI sites of pCDNA5insVector for expres-
sion from the CMV promoter (27–29).
Reporter constructs for activators and repressors were
cloned using BioBrick assembly, cut with SpeI and NotI,
and cloned between the SpeI and NotI sites of pCDNA5/
FRT/TO for mammalian expression (Invitrogen,
Carlsbad, CA, USA). Finally, to create combined TALE
repressor and shRNA reporter constructs, shRNA target
sites FF40 and FF60 were cloned into the NotI site of the
CFP reporter constructs of the TALE repressors.
Cell culture
Thehumanosteosarcoma-derivedepithelialcelllineU-2OS
(American Type Culture Collection, Manassas, VA, USA)
was maintained at 37 C, 5% CO2 in growth medium
(McCoy’s 5A medium supplemented with 10% FBS,
2mM L-glutamine, 100U/ml penicillin and 100mg/ml
streptomycin). The human embryonic kidney cell line
HEK293 (American Type Culture Collection, Manassas,
VA, USA) was maintained at 37 C, 5% CO2 in growth
medium (Dulbecco’s Modiﬁed Eagle Medium supple-
mented with 10% FBS, 2mM L-glutamine, 100U/ml
penicillin and 100mg/ml streptomycin). All transfections
were performed in 12-well plates seeded with  175000
cells using 3ml Lipofectamine LTX transfection reagent
and 1ml PLUS reagent (Invitrogen, Carlsbad, CA, USA).
AllTALEactivatortransfectionswereperformedinU-2OS
cells and used 25ng of TALE expression plasmid with
975ng of reporter plasmid in 1ml of growth medium.
TALE repressor experiments were performed in HEK293
cells and used 100ng of TALE expression plasmid with
10ng of reporter plasmid and 890ng of empty
pCDNA5insVector in 1ml of growth medium.
Microscopy
All microscopy was performed on live cells in glass-
bottomed wells (MatTek, Ashland, MA, USA) in phenol
red-free growth medium 24h post-transfection. Cells were
imaged using a Nikon TE-2000 microscope with a 20 
PlanFluor NA=0.5, DIC M/N2 objective and collected
with an ORCA-ER charge-coupled device camera. Data
collection and processing were performed with
Metamorph 7.0 software (Molecular Devices, Sunnyvale,
CA, USA). All images for a given experimental set and the
corresponding controls were collected with the same
exposure times, averaged over three frames and underwent
identical processing.
Flow cytometry
Approximately 30000 cells from each transfected well
were analyzed using an LSRII cell analyzer (BD
Biosciences, San Jose, CA, USA) in three biological
replicates. Cells were trypsinized with 0.1ml of 0.25%
trypsin-EDTA, pelleted and resuspended in 100mlo f
Dulbecco’s phosphate buffered saline containing 0.1%
FBS. For activator experiments, output was assayed 24h
post-transfection. The total AmCyan ﬂuorescent protein
(CFP) signal of mCH+cells was calculated by multiplying
the frequency of CFP+cells in the mCH+population by
the mean CFP signal of these double positive cells. The
fold change of AmCyan reporter ﬂuorescence was then
calculated as the ratio of total AmCyan ﬂuorescence
intensity of cells transfected with on-target TALE expres-
sion plasmids to cells transfected with reporter plus an
off-target input. For repressor experiments, outputs was
assayed 48h post-transfection and fold change of
AmCyan reporter ﬂuorescence was calculated as the
7586 Nucleic Acids Research, 2012,Vol.40, No. 15ratio of total AmCyan ﬂuorescence intensity of DsRED+
cells transfected with on-target TALE-shRNA expression
plasmids to DsRED+cells transfected with a reporter plus
an off-target input. To isolate the effects of TALEs and
shRNAs, expression constructs with different combin-
ations of TALE5R, TALE8R, FF4 and FF6 represented
different on- and off-target combinations depending on
the co-transfected reporter (Supplementary Table S9).
Quantitative PCR
For mRNA quantiﬁcation, mCherry positive U-2OS cells
were sorted and collected 48h post-transfection. RNA was
extracted from mCherry positive cells using the RNeasy
mini kit (Qiagen, Valencia, CA, USA), and mRNA levels
were quantiﬁed using the SYBR Green Assay (Applied
Biosystems, Foster City, CA, USA). The mRNA to
cDNA conversion was performed using the SuperScript
III RT kit (Invitrogen, Carlsbad, CA, USA). Three biolo-
gical replicates per sample and three technical replicates
per assay were analyzed for absolute quantiﬁcation of
mRNA levels in transfected cells. Two biological repli-
cates were analyzed for the mRNA levels quantiﬁcation
of OSGIN2 and ZC3H10 in cells transfected with TALE5
and TALE8, respectively. Relative transcript levels were
assessed using the 2
 Ctmethod (45) with GAPDH as a
reference gene. Statistical comparison between groups was
made by the pair-wise ﬁxed reallocation randomization
test using the publicly available Relative Expression
Software Tool (REST) (30).The off-target and on-target
DNA sequences of TALEs are detailed in Supplementary
Table S7. Primer sequences used for qPCR are detailed in
Supplementary Table S7.
Algorithm implementation
The algorithm was implemented in C+ +and the software
binaries are made available for download at http://silver
.med.harvard.edu/tale.html. Further details about the
algorithm are provided in Supplementary Methods. All
the results presented here were obtained by running our
software on the Harvard Medical School shared research
cluster of computation nodes.
RESULTS
Design and implementation of an algorithm for ﬁnding
orthogonal TALE binding sites
We ﬁrst sought to computationally design a set of TALEs
that bind to 20bp nucleotide sequences (20-mers) and are
orthogonal to human promoter regions. A TALE is
deﬁned to be orthogonal to a set of sequences if it is not
predicted to bind to any sequence in that set. In this
context, the number of base pair mismatches between a
TALE’s target sequence and a potential off-target
sequence (also referred to as the hamming distance
between the two sequences) is the main determinant of
the orthogonality of the TALE. Thus, a large hamming
distance between the TALE target site and a potential
off-target sequence corresponds to a lower chance of the
TALE binding to that off-target sequence.
TodesignsyntheticTALEsthatfunctionorthogonallyto
a set of non-intended target sites, we developed an
algorithm based on the farthest string problem. Given a
set, S, of n-mers deﬁned over an alphabet, , (e.g.
={A,C,G,T}), the objective of the farthest string
problem is to ﬁnd an n-mer (over the alphabet ) that has
the largest minimum hamming distance to n-mers in set S.
The farthest string problem belongs to a class of NP-hard
problems for which no polynomial time solution is known
to exist (31). Therefore, it may take an exponential amount
of time to enumerate all possible 4
20 nucleotide sequences
and test each to ﬁnd a 20-mer at a maximum hamming
distance from the set of genomic 20-mers. At present, no
algorithm exists to efﬁciently compute a set of such n-mers.
However,bydesigningcarefulheuristics,ouralgorithmcan
efﬁciently ﬁnd a list of 20-mers that are orthogonal to
human genome promoter regions by a hamming distance
of 3bp or more.
The steps followed by our algorithm are outlined in
Figure 3. We began by using a sliding window approach
toenumerateallpossible20-merspresentacrossbothDNA
strands in the promoter region of all genes in the human
genome. We deﬁne promoterregions as the 2000bpregions
upstreamoftheTSSofeachgene.Becausethepresenceofa
50 T has been demonstrated to be a necessary condition for
efﬁcient TALE binding, 20-mers that do not begin with T
were not considered, yielding a total of 17 10
6 20-mers
that are potential TALE binding sites (16). To further
reduce the number of 20-mers, the parental set of 17 10
6
20-mers was divided into subsets, such that each subset
could be represented by a single 20-mer within a 7bp
hamming distance from all sequences in that subset
(Supplementary Figure S1). Due to the reverse triangle in-
equality property of hamming distances, all 20-mers that
Figure 3. Flowchart enumerating the steps used in our algorithm to
compute orthogonal 20-mers. Steps 1 and 2 describe the process used
to reduce the set of genomic 20-mers. Steps 2 and 3 describe the process
of obtaining 20-mers orthogonal to the genomic set. Steps 2 and 3 of
the algorithm can be iterated until the desired number of orthogonal
sequences has been computed. Finally, the resulting sets of TALEs are
checked for mutual orthogonality to avoid cross-interference within the
synthetic circuits.
Nucleic Acids Research, 2012,Vol.40, No. 15 7587are at a minimum 10bp hamming distance from these rep-
resentative sequences will also be at a minimum hamming
distance of 3bp from the parental set of 17 10
6 genomic
20-mers (Supplementary Figure S1). Our algorithm uses
symbolic modeling techniques and Boolean algebra to
ﬁnd all possible 20-mers at a minimum hamming distance
of 10bp from representative sequences of each subset
(Supplementary Methods). Multiple solutions to ﬁnding
such subsets exist and each solution is typically comprised
of 12000–15000 subsets, each having a representative
20-mers. By generating multiple sets of representative
20-mers and applying our algorithm iteratively, we
identiﬁed over 180 potential binding sites for synthetic
TALEs at a minimum hamming distance of 3bp from
any 20-mer in the promoter regions of the human genome
(Supplementary Table S2).
We chose to generate and characterize 8 of these 180
TALEs predicted to be orthogonal to human promoter
regions (Table 1). Chosen TALEs had a hamming distance
of 3bp from all 2000bp genomic promoter regions and a
hamming distance of 4bp from 500bp genomic promoter
regions. The hamming distance to the more stringent 500bp
genomic promoter regions was used as an additional criter-
ion as native transcription factor binding sites are known to
be highlyconcentratedwithin these 500bpregions proximal
to the TSS (32–35). From our set of 150 synthetic TALEs,
100proteinspossessedaminimumhammingdistanceof4bp
from500bpproximalpromoterregions,whiletheremaining
50 proteins had a hamming distance of 3bp. To minimize
potential cross-activation between the selected TALEs, we
alsoensuredthattheeightselectedTALEswerepredictedto
be mutually orthogonal.
In vivo characterization demonstrates activity and mutual
orthogonality of synthetic TALE activators
To generate each of our eight computationally designed
TALEs for assaying in vivo, a library of subparts was
synthesized containing both individual di-residue repeats
and each pair-wise combination of repeats, codon-
optimized for expression in mammalian cells. Individual
TALEs were created using a hierarchical, modular cloning
strategy that leverages type IIS restriction enzymes to
readily combine members of a library of subparts into
any desired TALE (Supplementary Figure S2). The
modular cloning scheme we use is similar to the techniques
reported in the recent literature (18,19,20,36,37). For each
protein, both native NLSs were replaced with eukaryotic
versions, and the native activation domain was replaced
Table 1. Constituent RVDs and cognate binding sites of the 8 TALEs that were constructed and functionally
characterized
0 1 2 3 4 5 6 7 8 9 1 01 11 21 31 41 51 61 71 81 9
HD NI NI NG NI  HD NG NG  NI  HD NI NI NI  HD NG HD HD NG NG  TALE 1 
T C A A T A C T T A C A A A C T C C T T
HD HD  NI  HD HD NI NI NI  NG NG HD NI NI  HD NI  HD NG NG NG  TALE 2 
T C C A C C A A A T T C A A C A C T T T
HD NI  NG HD NG NI  HD NI NI  HD NI  HD NG NI  HD NG NI  NG NG  TALE 3 
T C A T C T A C A A C A C T A C T A T T
HD HD HD  NI NI  NG NI  HD NI  HD NG NI  NG NI NI  HD NI  HD NI  TALE 4 
T C C C A A T A C A C T A T A A C A C A
NI NI  HD NG NG NI  HD HD NG NG HD NG HD NI NI  HD NI  HD NI  TALE 5 
T A A C T T A C C T T C T C A A C A C A
NI  NG HD HD NG HD NG NG NI  HD NI NI  NG NI  NG HD HD HD NI  TALE 6 
T A T C C T C T T A C A A T A T C C C A
NI  HD NG NG NI  HD HD HD NG NI NI  HD HD HD NI NI  NG NG NG  TALE 7 
T A C T T A C C C T A A C C C A A T T T
NI  NG NI  HD NG NI  NG HD HD  NI NI  NG HD HD  NI NI  HD NG NG  TALE 8 
T A T A C T A T C C A A T C C A A C T T
HD HD NG HD HD HD HD NI  HD HD NG NG NG NI NI  NG NG NG NG TALE
OSGIN2 T C C T C C C C A C C T T T A A T T T T
NI HD HD NI NG NI NG HD HD HD NI NG HD HD NI NI HD NG HD TALE 
ZC3H10 T A C C A T A T C C C A T C C A A C T C
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domain. TALEs were expressed from the cytomegalovirus
(CMV) promoter and tagged with an auto-catalytically
cleaved t2A peptide fused to mCherry ﬂuorescent
protein as a transfection control (Figure 4A).
The ability of our synthetic proteins to recognize a
binding site and activate gene expression was tested by
co-transfecting TALE expression constructs with reporter
plasmids containing a 20-mer binding site driving expres-
sion of two tandem copies of the CFP fused to an NLS
(Figure 4B). Experiments were performed in the U-2OS
human osteosarcoma cell line and assayed by ﬂuorescence
microscopy and ﬂow cytometry 24h post-transfection.
Each TALE was co-transfected with its corresponding
binding site reporter plasmid to determine if it was
capable of activating transcription from its targeted
reporter, as well as with reporter plasmids containing
binding sites for the seven other constructed TALEs in
order to ensure that all proteins are mutually orthogonal.
Results from ﬂuorescence microscopy indicate that all
TALEs were efﬁciently expressed, as determined by
presence of mCherry positive cells (Supplementary
Figure S3). Furthermore, the TALEs efﬁciently activated
gene expression from promoters containing their cognate
binding site and not those targeted by other TALEs in the
set, indicating that our synthetic TALEs function in a
mutually orthogonal manner (Figure 5A). Flow cytometry
was performed to quantify TALE-activated CFP expres-
sion from each promoter. Activity was measured as the
total CFP signal of mCherry positive cells. As a control,
an off-target TALE was co-transfected with each TALE
reporter plasmid and the level of activation for each syn-
thetic TALE was calculated relative to this off-target
control. These results conﬁrmed our ﬂuorescence
microscopy ﬁndings, with synthetic TALEs demonstrating
a 10- to 102-fold induction of the CFP reporter with no
signiﬁcant signal observed for off-target binding sites
(Figure 5B and Supplementary Table S1).
Synthetic TALEs do not activate transcription of a set of
off-target endogenous genes
To investigate the orthogonality of our TALEs to poten-
tial genomic promoter binding sites, we began by assessing
the effect of target site mismatches on the ability of
TALEs to bind a given 20-mer. It has previously been
shown that TALE activity generally decreases with the
number of mutations in its target site (18,22,37,38,39).
However, as positional and contextual effects of these mu-
tations have also been reported, it is important to analyze
the speciﬁc effect of mutations in the context of our
TALEs that have a different protein architecture and
bind to longer DNA sequences (20 bp) than those
previously studied. TALE8 was chosen as a representative
protein and reporter constructs were generated with
20-mers at a hamming distance of 1–7 from TALE8’s
on-target binding site. To avoid potential position-speciﬁc
bias, mismatches were distributed evenly throughout the
binding sites (Figure 6A). TALE8 was co-transfected with
each reporter construct, and reporter expression was
assayed by ﬂuorescence microscopy and ﬂow cytometry
with TALE5 serving as an off-target control. Expression
from reporter constructs was observed to decrease with
the hamming distance and 20-mers at a hamming
distance of 3bp from the on-target site exhibited output
signal that was one-tenth of the full signal, and 20-mers at
a hamming distance of 4bp or more from the on-target
site exhibited an output signal comparable to background
(Figure 6B).
We next sought to ascertain the inﬂuence of mismatch
position on protein function. Three additional reporter
plasmids were generated for TALE8 with a hamming
distance of 3bp. The positions of these mismatches were
localized to either the 50-end, the 30-end or the center of the
target site (Figure 6A). Our results illustrate that
mismatches in the 50-end and center of the target site
abolish TALE activated expression, while mismatches in
the 30 end appear to have less of an impact, more closely
resembling mismatches uniformly distributed throughout
the binding site (Figure 6C). These results indicate that the
location of mismatches should be considered when design-
ing orthogonal TALEs. Within the 2kb promoter regions,
the longest matching endogenous sequences to our
designed eight TALEs were at most 14bp long and these
off-target sequences had four or more mismatches in pos-
itions 14–20. Thus, our constructed TALEs satisfy the
combined constraints set by number and position of
mismatches in Figure 6 (Supplementary Table S3).
To more directly characterize the orthogonality of our
synthetic TALEs to endogenous promoter regions in vivo,
we measured mRNA expression levels from the most
likely predicted target genes following transfection with
two representative TALEs, TALE5 and TALE8. The
nearest predicted off-target sequence for TALE5 was in
the promoter of oxidative stress induced growth inhibitor
family member 2 (OSGIN2), and for TALE8 the nearest
predicted off-target sequence was in the promoter of
Figure 4. (A) Schematic of TALE expression constructs. Each TALE
coding region was cloned into a mammalian expression vector down-
stream of the CMV promoter. All synthetic TALEs were also tagged
with an self-cleaving t2A:mCherry ﬂuorescent protein as a transfection
control. (B) Schematic of TALE reporter constructs. Reporter con-
structs were generated by cloning a 20bp TALE target sequence
upstream of a minimal TATA box separated by a 78bp spacer
region. Binding of a TALE activator to the 20bp target sequence
drives expression of two tandem copies of NLS-tagged CFP cloned
downstream of the TALE-responsive promoter as an output for
TALE functionality.
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Figure 6. Effect of binding site mutations on TALE-mediated transcriptional activation. (A) TALE8 activity in the presence of an increasing number
of uniformly distributed binding site mismatches. BS-8 is the corresponding binding site for TALE8 with additional binding sites tested at a hamming
distance (HD) of 1–7bp from BS-8 (HD-1–HD-7). The ability of TALE8 to activate CFP expression from each binding site reporter was measured
by ﬂow cytometry relative to TALE5 as an off-target control. The presence of two or more mismatches in the binding site signiﬁcantly decreases the
ability of TALE8 to activate gene expression, with binding sites at a hamming distance of more than 3bp displaying no reporter activity. (B) Effect
of binding site mismatch position on TALE activation. The ability of TALE8 to activate gene expression from binding sites with a hamming distance
of 3bp was tested with the position of the mismatches either uniformly distributed, HD-3, localized to the 50-end of the binding site, HD-3(50), to the
middle of the binding site, HD-3(M) or to the end of the binding site, HD-3(30). (C) Tested DNA binding sequences. Underlined nucleotides
represent mismatches with respect to BS-8.
7590 Nucleic Acids Research, 2012,Vol.40, No. 15zinc-ﬁnger CCCH-type containing 10 (ZC3H10). The
targets of each TALE chosen for analysis were determined
based on the presence of the closest off-target binding site,
having a minimum number of mismatches, in the 500bp
region upstream of the TSS. As a positive control, we
designed two TALEs, TALE-OSGIN2 and TALE-
ZC3H10, that are predicted to effectively bind in the
500bp upstream promoter regions of OSGIN2 and
ZC3H10, respectively. Off-target sequences for TALE5
and TALE8 and target sequences for TALE-OSGIN2
and TALE-ZC3H10 are listed in Supplementary Table
S7. All TALEs were transfected in U-2OS cells and the
fold change in mRNA level relative to a mock-transfected
control was measured at 48h post-transfection by qPCR
(Figure 7).
Results from qPCR demonstrate that while our positive
control, TALE-OSGIN2, is capable of inducing OSGIN2
mRNA expression by 4.8-fold, no signiﬁcant induction is
observed following transfection with TALE5 (Figure 7A).
Similarly, transfection with TALE-ZC3H10 leads to a sig-
niﬁcant induction of targeted ZC3H10 mRNA, while no
signiﬁcant induction is observed following transfection
with TALE8 (Figure 7B). In order to ensure that an
adequate amount of TALE transcription factor was ex-
pressed in cells, we analyzed the fold induction in
mRNA expression of off-target genes from TALE5 and
TALE8 with 10  higher amount of TALE expression
plasmid (Figure 7). We observed no signiﬁcant induction
of off-target genes even in the presence of the higher
concentration of TALE expression plasmid. To further
investigate the orthogonality of our synthetic TALEs, we
assayed mRNA expression of the next four nearest
predicted target genes of TALE5 and the next three
nearest predicted target genes of TALE8 (Figure 7). In
all cases, no signiﬁcant induction of potential target
genes was seen relative to mock-transfected controls,
providing further evidence for the orthogonality of these
TALEs relative to human promoter regions.
Construction and characterization of TALE repressors
Next, we designed and tested TALE repressor proteins
composed of our orthogonal TALE DNA binding
domains. We generated TALE repressors TALE5R and
TALE8R, by replacing the VP64 activation domain with
the KRAB transcriptional repression domain in TALE5
and TALE8 constructs, respectively (Figure 8A). The
ability of these TALEs to repress transcription was
tested by co-transfecting them with CMV-driven CFP
expression vectors containing the cognate TALE binding
site located on the transcriptional start site of the CMV
promoter. TALE repressors efﬁciently repressed CFP
expression from 36- to 97-fold compared to off-target
TALE controls (Figure 8).
Finally, we demonstrated the ability to tightly repress
gene expression to near background levels by combining
the TALE repressors with shRNAs targeting the same
transcripts. We designed expression constructs that
co-express a TALE repressor, an shRNA and the DsRed
ﬂuorescent protein from the same promoter. The shRNAs
were generated in the miR30 context and embedded within
the SV40 intron in the DsRED red ﬂuorescence protein
gene (40,41). We used the shRNAs, ‘FF4’ and ‘FF6’,
previously designed to target the Fireﬂy Luciferase gene
as they are commonly used as off-target negative control
shRNAs and are reported to be orthogonal to endogenous
transcripts (41). When co-expressed, the TALE and
shRNA combination repressed CFP expression from
740- to 4853-fold. Of note, the level repression mediated
by the TALE repressors alone was at least 5-fold higher
than that of the shRNAs expressed alone.
AB
Figure 7. Characterization of TALE-mediated off-target endogenous gene activation in vivo. Fold change in mRNA levels of potential target genes
following TALE expression. mRNA levels of the most likely target genes of TALE5 and TALE8 were measured by qPCR 48h post-transfection with
the corresponding TALE construct and plotted as fold change over mock-transfected cells. TALE-OSGIN2 and TALE-ZC3H10 are the positive
control TALEs predicted to activate the two closest off-target genes of TALE5 and TALE8 respectively. (A) A 4.8-fold induction of nearest target
gene OSGIN2 by the positive control TALE-OSGIN2, and no signiﬁcant change in mRNA levels of OSGIN2 and the other four nearest target genes
of TALE5 is observed in response to TALE5. The 10  higher concentration (250ng) of TALE5 also shows no signiﬁcant induction in mRNA levels
of its off-target gene OSGIN2. (B) The positive control TALE-ZC3H10 leads to a modest but signiﬁcant induction of nearest target gene (ZC3H10)
of TALE8. There is no signiﬁcant change in mRNA levels of the four nearest target genes of TALE8 in response to TALE8 expression. Asterisk
indicates P<0.03.
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Robust synthetic networks would enable the ability to
sense a wide variety of cellular cues and respond in a
desired fashion to modulate cell behavior, but so far
efforts to design these networks have been limited by
the reliance on a small set of commonly used gene
regulatory components. A large set of mutually orthog-
onal and modular regulatory components would be a
useful tool for generating such networks. Additionally,
using components for which interference with the host
cell’s machinery is minimized would help to reduce
the chance of unwanted cellular behaviors and system
failures.
TALE transcription factors present a powerful tool
with many potential applications including use as a set
of reliable gene regulatory components for synthetic
gene circuits. However, their utility is limited by degener-
ate binding and the strong potential for off-target effects
(6–8,16,19). While recent work has demonstrated the
ability of designer TALE activators to turn on expression
of desired genes, they have not been optimized to
minimize off-target effects and likely activate the expres-
sion of genes other than those intended (Supplementary
Methods) (37). Here, we present a novel and general
method to design TALE DNA binding domains with
cognate binding sites orthogonal to a given set of
sequences. We create a set of synthetic TALE activators
and repressors that speciﬁcally recognize and act upon
20bp binding sites that are at least 3nt mismatches
away from 20bp sequences contained in all putative
human promoter regions.
Applying our algorithmic approach to ﬁnd TALEs that
are speciﬁc to a given endogenous gene promoter should
be relatively less computationally intensive as the search
space for such TALEs is very small compared to the ex-
ponentially large search space for TALEs orthogonal to
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Figure 8. Schematics and characterization of TALE repressor-shRNA constructs. (A) The VP64 activation domain of the TALE activators was
replaced with the KRAB repression domain and the resulting TALE repressor coding region was cloned into a mammalian expression vector
together with a self-cleaving DsRed:t2A ﬂuorescent protein. Synthetic shRNAs were expressed from an intron in the DsRed gene. (B) Reporter
constructs were generated by cloning a 20bp TALE target sequence into the TSS of the CMV promoter. On binding its recognition site in the
promoter, the TALE represses the constitutive expression of the downstream CFP protein. The reporter construct also contains a single copy of
the cognate shRNA recognition sequence in the 30-UTR, which when recognized by the target shRNA leads to degradation of the CFP transcript.
(C) TALE repressors, TALE5R and TALE8R were combined with shRNAs, FF4 and FF6, to repress CFP expression from reporter constructs
carrying cognate TALE and shRNA recognition sites. Repressions ranged 6  in the case of shRNA alone to  4800  in the case of shRNA+TALE
repressor combination.
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possible TALEs that can bind on a given promoter
region, the heuristics presented here based on reverse
triangle inequality property of hamming distance can be
applied to efﬁciently screen for TALEs that are orthog-
onal by a given number of base pairs to the rest of the
promoters in the genome.
Our synthetic TALE activators displayed high activa-
tion of on-target reporters with levels of activation
ranging from 10-fold up to 102-fold and are mutually
orthogonal. These activation levels are similar to other
recently reported TALEs designed to function in mamma-
lian cells, although we employ a different promoter
architecture for TALE expression (37). We further
characterized the effects of binding site mismatches on
TALE orthogonality by selecting a single TALE and
generating synthetic target sites containing between 1
and 7 evenly distributed mismatches. We found that the
activation dropped off quickly with an increase in
hamming distance—indicating the minimum hamming
distance for orthogonality of our TALEs recognizing
20bp falls in the range of 3–4bp.
We also found that the distribution of mismatches in
the binding site affects TALE protein activity. Testing
20bp TALE binding sites with sets of three mismatches
located at either the 50 end of the binding site, the 30 end of
the binding site, the middle of the binding site or
distributed uniformly throughout the 20-mer, we
observed that 3bp mismatches are able to abolish TALE
activation when these mutations are introduced at either
the 50 end or in the middle of TALE binding site
(Figure 6C). Three consecutive mutations introduced at
the 30 end of binding site show low off-target activity,
about one-tenth of the full factor, as did the three
mutations distributed throughout the binding site. These
results suggest that for binding sites with a 3bp hamming
distance the position of the mutations should be
considered.
With these results in mind, we compared the set of 180
computationally derived orthogonal TALE binding sites
to all possible 20-mers in 2000bp upstream promoter
regions of the human genome. We found that for
genomic sites predicted to be the most likely targets for
our synthetic TALEs, the longest region with perfect
complementarity from the 50 end was <14bp long for
the majority of our synthetic target sites. Furthermore,
within this small subset of target sites possessing stretches
of sequence complementarity, four or more mutations are
typically found between positions 13–20bp, suggesting
that likelihood of a synthetic, orthogonal TALE efﬁciently
binding to a genomic promoter site is extremely low
(Supplementary Table S3).
To provide further functional evidence for the orthog-
onality of our synthetic TALEs to genomic promoter
regions in vivo, we measured mRNA expression levels
from the nine most likely target genes following transfec-
tion with two representative TALEs. All potential target
genes displayed no increase in mRNA expression levels
relative to control, while TALEs designed to speciﬁcally
target two of those same genes were able to induce mRNA
expression up to 4.8-fold. While we cannot rule out the
activation of other potential off-target genes by our
TALEs, nor the activation of genes by TALE binding to
distant enhancer regions outside of the 2kb promoter
regions, these results, combined with data detailing the
effect of target site mismatches and bioinformatics
approaches, provide evidence supporting the ability of
our TALEs to function orthogonally to the human
promoter regions.
Next, we designed TALE repressors by replacing the
VP64 activation domain in the 30 constant back region
with the KRAB repressor domains. We assayed two syn-
thetic TALE repressors made from our orthogonal TALE
DNA binding domains, along with two synthetic
shRNAs, and demonstrate that TALE repressors can
provide strong transcriptional repression. The TALE-
mediated gene repression was more potent than that
accomplished by the two shRNAs tested using the same
assay. Double repression of a target gene by the LacI
transcriptional repressor and an shRNA was previously
reported to be capable of tightly controlling transgene ex-
pression (42). We show that such regulation is also
possible by combining TALE repressors and shRNAs.
Combined repression reduced the expression level of
target protein to near background levels. As TALEs are
highly programmable compared to LacI this result allows
for the generation of a set of tightly repressed gene
modules and opens the possibility of tightly regulating
endogenous target genes. TALE repressors have been
shown to be a powerful tool for regulating the expression
of genes in yeast and plants (43,44). Our results demon-
strate that TALE repressors can work efﬁciently in
mammalian cells as well.
Finally, it is worth noting that our proposed algorithm
can easily accommodate additional constraints. For
example, it can be readily adapted to identify orthogonal
sequences of different lengths and for different sequences
including the genomes of other organisms. It could also be
modiﬁed to ﬁnd TALEs that have larger hamming
distances to especially critical promoter regions.
In addition to addressing the problem of generating syn-
thetic circuit components with minimal effects on en-
dogenous genes, the methods that we employ to generate
TALEs are general and can be applied to any system
requiring speciﬁc DNA binding domains. Other potential
applications of orthogonal TALE DNA binding domains
include TALE nucleases, TALE recombinases or TALE-
based DNA methylases, and TALE transcriptional activa-
tors and repressors that speciﬁcally target endogenous
genes. The computational approach and transcription
factors presented here provide important tools
and methods for the precise engineering of biological
systems.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Tables 1–10, Supplementary Figures 1–7,
Supplementary Methods and Supplementary References
[46–48].
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